08.31.07
SAFC, a member of the Sigma-Aldrich Group, has announced a $4.5 million capacity expansion program at its SAFC Pharma high-potency API (HPAPI) facility in Madison, WI. The program will add cGMP pilot plant and kilo lab capacity and complement the new XRPD (X-ray Powder Diffraction) analytical equipment for advanced solid form testing, which the company expects to be operational this month. The expansion is scheduled to start in early 2008.
SAFC is adding two 400-liter cGMP pilot plant reactors and two 100-liter cGMP portable jacketed reactors into a 1200-sq.-ft. large-scale kilo lab. The addition will enable larger-scale chromatography for process purification. The company also installed and qualified a Bruker D8 Advance X-ray Diffractometer for solid-form testing and analysis, providing U.S. customers with on-site cGMP and XRPD analysis of potent compounds. Rapid sample testing at the Madison site combines with data analysis and evaluation performed at SAFC Pharmorphix facilities in the U.K.
SAFC Pharmorphix specializes in solid-form research and is completing a multi-phase, $1.2 million expansion program at its labs. SAFC president, Frank Wicks, commented, “As regulatory requirements align with the increasing complexity of drugs, solid-form testing, analysis and optimization are becoming key elements in the drug development process. Additional and enhanced capabilities at SAFC Pharma’s Madison facility mark a timely expansion to the scope and value of our HPAPI offering and are reflective of SAFC’s ability to support its customers throughout the drug development cycle.”
SAFC is adding two 400-liter cGMP pilot plant reactors and two 100-liter cGMP portable jacketed reactors into a 1200-sq.-ft. large-scale kilo lab. The addition will enable larger-scale chromatography for process purification. The company also installed and qualified a Bruker D8 Advance X-ray Diffractometer for solid-form testing and analysis, providing U.S. customers with on-site cGMP and XRPD analysis of potent compounds. Rapid sample testing at the Madison site combines with data analysis and evaluation performed at SAFC Pharmorphix facilities in the U.K.
SAFC Pharmorphix specializes in solid-form research and is completing a multi-phase, $1.2 million expansion program at its labs. SAFC president, Frank Wicks, commented, “As regulatory requirements align with the increasing complexity of drugs, solid-form testing, analysis and optimization are becoming key elements in the drug development process. Additional and enhanced capabilities at SAFC Pharma’s Madison facility mark a timely expansion to the scope and value of our HPAPI offering and are reflective of SAFC’s ability to support its customers throughout the drug development cycle.”